Globe Life
GLNYSEUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $163.46 Prior regular-session close from the quote source.
- $160.85–$163.73 Regular-session low and high so far today.
- 389.6K Regular-session shares traded · Nov 11, 4:00 PM ET.
- Not yet confirmed The company has not confirmed its next report date. Reported quarters are available in the chart’s Earnings view.
- $129.21–$191.55 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own GL if Globe Life creates durable shareholder value by selling straightforward life insurance products with disciplined underwriting and capital allocation, turning steady premium cash flows and invested float into predictable earnings, high operating cash flow and.
GL price history
Loading recent earnings…
Investment thesis
What must happen next
Stable, high cash conversion from underwriting and premium collections is the primary engine that funds dividends, buybacks and equity growth, and will persist because current underwriting economics have historically converted to consistent operating cash flow.StrengtheningMateriality: High
operating_cash_flow = 1,396,391,000 USD (annual, FY2025). If operating cash flow stays predictable, the company can fund shareholder returns and absorb shocks without diluting equity; if it falls, capital returns and the multiple both compress.
Watch: A sustained deterioration in mortality or lapse rates (large catastrophe, pandemic or changes in policyholder behaviour) that raises claims and reserves.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
operating_cash_flow = 1,396,391,000 USD (annual, FY2025).
Open source ↗Revenue growth (premiums) has been steady and will continue if the company maintains competitive pricing and distribution reach for its core life products, because product simplicity reduces underwriting friction and supports scalable sales.StrengtheningMateriality: High
revenue rose from 5,112,038,000 USD (FY2021) to 5,994,318,000 USD (FY2025), showing multi-year top-line growth. Sustained premium growth feeds investment float and underwriting scale; if premium sales stall or price competition intensifies, growth and float will slow and ROE will fall.
Watch: Loss of key distribution channels (direct response or agency networks) or regulatory limits on marketing that reduce new policy sales.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
revenue rose from 5,112,038,000 USD (FY2021) to 5,994,318,000 USD (FY2025), showing multi-year top-line growth.
Open source ↗Diluted EPS will continue to compound because modest net income growth combined with disciplined capital allocation (limited dilution and buybacks) drives per-share earnings higher.StrengtheningMateriality: Medium
eps_diluted increased from 9.04 USD (FY2022) to 14.07 USD (FY2025), reflecting rising net income per share. If EPS keeps compounding, shareholders get both growing intrinsic value and a solid yield on price; if EPS falls or share count rises materially, total shareholder return suffers.
Watch: Management shifts to capital-hoarding or is forced to issue equity to meet capital/reserve needs.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
eps_diluted increased from 9.04 USD (FY2022) to 14.07 USD (FY2025), reflecting rising net income per share.
Open source ↗Globe Life’s growing equity base and asset size provide a capital buffer to absorb periodic underwriting/investment volatility and support ratings and dividend/buyback capacity.StrengtheningMateriality: Medium
equity increased from 3,949,577,000 USD (FY2022) to 5,974,579,000 USD (FY2025), showing capital build. A strong balance sheet preserves operating freedom through stress periods; if equity is eroded by reserve builds or impairments, capital allocation and rating will be constrained.
Watch: Material statutory reserve increases or adverse actuarial rulings that force large, one-time equity charges.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
equity increased from 3,949,577,000 USD (FY2022) to 5,974,579,000 USD (FY2025), showing capital build.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Stable, high cash conversion from underwriting and premium collections is the primary engine that funds dividends, buybacks and equity growth, and will persist because current underwriting economics have historically converted to consistent operating cash flow. If operating cash flow stays predictable, the company can fund shareholder returns and absorb shocks without diluting equity; if it falls, capital returns and the multiple both compress.
Revenue growth (premiums) has been steady and will continue if the company maintains competitive pricing and distribution reach for its core life products, because product simplicity reduces underwriting friction and supports scalable sales. Sustained premium growth feeds investment float and underwriting scale; if premium sales stall or price competition intensifies, growth and float will slow and ROE will fall.
Diluted EPS will continue to compound because modest net income growth combined with disciplined capital allocation (limited dilution and buybacks) drives per-share earnings higher. If EPS keeps compounding, shareholders get both growing intrinsic value and a solid yield on price; if EPS falls or share count rises materially, total shareholder return suffers.
Globe Life’s growing equity base and asset size provide a capital buffer to absorb periodic underwriting/investment volatility and support ratings and dividend/buyback capacity. A strong balance sheet preserves operating freedom through stress periods; if equity is eroded by reserve builds or impairments, capital allocation and rating will be constrained.
All standing thesis claims
Original report summary
Globe Life creates durable shareholder value by selling straightforward life insurance products with disciplined underwriting and capital allocation, turning steady premium cash flows and invested float into predictable earnings, high operating cash flow and.
Bull case and bear case
Bull case and bear case for Globe Life
Where the evidence on Globe Life stands: Strengthening on the latest evidence (Nov 7, 2026). Of its 4 thesis points, 4 strengthening.
Bull case: what the evidence supports
Stable, high cash conversion from underwriting and premium collections is the primary engine that funds dividends, buybacks and equity growth, and will persist because current underwriting economics have historically converted to consistent operating cash flow.
Revenue growth (premiums) has been steady and will continue if the company maintains competitive pricing and distribution reach for its core life products, because product simplicity reduces underwriting friction and supports scalable sales.
Diluted EPS will continue to compound because modest net income growth combined with disciplined capital allocation (limited dilution and buybacks) drives per-share earnings higher.
Globe Life’s growing equity base and asset size provide a capital buffer to absorb periodic underwriting/investment volatility and support ratings and dividend/buyback capacity.
Bear case: what would count against it
A sustained deterioration in mortality or lapse rates (large catastrophe, pandemic or changes in policyholder behaviour) that raises claims and reserves.
Loss of key distribution channels (direct response or agency networks) or regulatory limits on marketing that reduce new policy sales.
Management shifts to capital-hoarding or is forced to issue equity to meet capital/reserve needs.
Thesis-Break Engine
Thesis-break watch · Globe Life
Loading the break-condition record for Globe Life.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedReported results of operations (earnings release).
Globe Life filed an SEC 8-K on 2026-10-21: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
- MixedDirector or principal officer change.
Globe Life filed an SEC 8-K on 2026-08-07: Director or principal officer change. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Globe Life filed an SEC 8-K on 2026-07-22: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- A sustained deterioration in mortality or lapse rates (large catastrophe, pandemic or changes in policyholder behaviour) that raises claims and reserves.
- Loss of key distribution channels (direct response or agency networks) or regulatory limits on marketing that reduce new policy sales.
- Management shifts to capital-hoarding or is forced to issue equity to meet capital/reserve needs.
- Material statutory reserve increases or adverse actuarial rulings that force large, one-time equity charges.
GL news
Loading headlines…
Financial statements
GL income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
GL: quick answers
- Which well-known investors own GL?
- 1 of the 37 well-known funds tracked here reported GL shares in their latest 13F filing. By share of the fund's portfolio: Bridgewater Associates (Ray Dalio), 0.1%. Fund portfolios
GL in well-known investors’ portfolios
1 of 37 funds reported GL shares in their latest 13F filing. A 13F shows quarter-end positions and arrives up to 45 days later.
| Fund | Of its portfolio | Value | Change | Quarter |
|---|---|---|---|---|
| Ray DalioBridgewater Associates | 0.05% | $11.8M | +1,190% | Q2 2026 |